Tirzepatide 40 mg is the highest stocked lyophilised LY3298176 vial in the BuyRetaUK range — the extended-programme presentation for sustained laboratory workflows, higher-throughput studies and multi-plate research where consolidating peptide mass into fewer batches improves per-milligram economics and simplifies batch-to-batch reconciliation.
Tirzepatide 40 mg is a 40-milligram lyophilised LY3298176 vial released to ≥99% HPLC-UV with mass-spectrometric identity. It is the largest stocked presentation in the BuyRetaUK Tirzepatide catalogue, chosen for extended laboratory programmes, higher-throughput workflows and improved per-milligram cost efficiency.
Tirzepatide 40 mg is a single lyophilised vial containing 40 milligrams of Tirzepatide (LY3298176), a synthetic dual GLP-1 / GIP receptor agonist. It is the highest stocked presentation at BuyRetaUK and the natural choice for laboratories running sustained programmes or higher-throughput workflows where consolidating peptide mass into fewer batches simplifies a study.
For receptor pharmacology see Tirzepatide Mechanism of Action; for the cornerstone explanatory guide see What is Tirzepatide?.
For routine general-purpose programmes step down to the Tirzepatide 20 mg vial; for pilot or method-development work step down further to the Tirzepatide 10 mg vial. Every stocked strength shares the same release specification — see the Strengths Hub for the full comparison.
Every vial ships with a batch-specific COA · UK dispatch
The 40 mg vial is released under the same synthesis and analytical framework as every other stocked Tirzepatide strength — see laboratory quality for methodology and acceptance criteria.
Reverse-phase HPLC quantifies purity as a percentage of total peak area. Release specification: ≥99%.
Learn more →Certificate of AnalysisEvery batch ships with a batch-specific COA reporting identity, purity and appearance.
Learn more →Laboratory QualityIndependent third-party analysis, temperature-controlled UK storage and full batch traceability.
Learn more →Batch VerificationCross-reference the batch number printed on your vial against our live COA library.
Learn more →Storage StandardsLyophilised at 2–8°C protected from light. Reconstituted stability ~30 days at 2–8°C.
Learn more →Every 40 mg vial ships with a batch-specific Certificate of Analysis. Cross-check the batch number against the verification library on arrival — a section-by-section walk-through of the certificate lives in the Certificate of Analysis guide.
The 40 mg vial is released against the same ≥99% HPLC-UV area-percent specification as the 10 and 20 mg presentations, with orthogonal identity confirmation by ESI-MS. Method detail lives in Tirzepatide Purity.
Store sealed 40 mg vials at −20 °C for extended holding; a 40 mg reconstitution particularly benefits from a disciplined aliquot plan at reconstitution time, with each aliquot frozen once and thawed once. Full cold-chain framework in Tirzepatide Storage & Reconstitution.
For a 40 mg vial the highest-return single decision is to aliquot the entire reconstituted stock at reconstitution time.
Fix reconstitution volume so the working concentration matches the rest of the programme without recalculation between batches.
Order 40 mg vials to cover the sustained programme without over-committing shelf life at ambient storage.
Cross-reference each vial's batch number against the published Certificate of Analysis before opening.
It carries the largest stocked peptide mass in the BuyRetaUK Tirzepatide catalogue, so a sustained multi-week programme can run from a smaller number of batches. That reduces batch changeovers mid-study, simplifies reconciliation and typically improves per-milligram cost.
Reconstituting a 40 mg vial in 4 mL of bacteriostatic water yields 10 mg/mL; in 8 mL yields 5 mg/mL; in 2 mL yields 20 mg/mL. The reconstitution calculator returns the exact diluent volume for any target working concentration.
The full 40 mg dissolves in a single reconstitution — the peptide is not diluted by choosing a larger vial. Working concentration is a function of vial mass divided by diluent volume, so the same target concentration is achievable from any strength.
40 mg typically improves per-milligram economics compared with the 20 mg mid-range vial while consolidating a workflow onto fewer batches. The trade-off is a longer in-use window for the reconstituted stock — disciplined aliquoting at reconstitution keeps this manageable.
Usually not. Method development or short pilots are better served by the 10 mg entry vial or the 20 mg mid-range vial, where a whole vial is realistically consumed in a short window.
No. Every stocked Tirzepatide vial is manufactured under the same synthesis and release framework, with identical HPLC-UV purity and ESI-MS identity confirmation reported on the batch-specific Certificate of Analysis.
Reconstitute once, then split the entire working stock into single-use aliquots at reconstitution time, sized to the daily or weekly consumption of the workflow. Freeze each aliquot once and thaw once — the Tirzepatide storage guide covers freeze-thaw handling in detail.
No. All BuyRetaUK Tirzepatide vials, including the 40 mg vial, are supplied for in-vitro laboratory research only and are not intended for human or veterinary administration.
Peer-reviewed citations are added as each article is expanded. See our editorial standards for our sourcing and accuracy commitments.
The BuyRetaUK editorial team publishes laboratory-focused reference content on research peptides, analytical methods and Certificates of Analysis. All articles are written for in-vitro research contexts only.
View profile →Every editorial article is reviewed against our accuracy commitment and quality-assurance checklist before publication. Named reviewer profiles are added as our reviewer network expands.
View profile →Every article follows a documented editorial process — sourcing, scientific review, update cadence and correction policy — so researchers can rely on what we publish.
Read the full editorial standards →Educational first. Each step is optional — start wherever you are in your research.
Dual GIP/GLP-1 receptor overview and research framing.
How dual receptor engagement drives the incretin response.
Published evidence base, SURPASS & SURMOUNT programmes, laboratory applications.
Phase 3 SURPASS & SURMOUNT read-outs and the peer-reviewed literature.
Dual vs triple incretin agonist — how they differ.
HPLC purity and Certificate of Analysis verification.
Lyophilised storage, bacteriostatic water reconstitution, in-use stability.
Every tirzepatide vial strength available.
UK commercial hub — lab data, COAs and dispatch.
Triple vs dual incretin agonist — receptor profile and research framing.
View comparison →Side by sideSelective GLP-1 agonist vs dual GIP/GLP-1 agonist — receptor pharmacology and evidence comparison.
View comparison →Multi-compoundAll GLP-1 / GIP / glucagon research compounds in one place.
View comparison →How to store lyophilised research peptides and reconstitute them correctly for laboratory use.
4 min read →RetatrutideA laboratory overview of retatrutide (LY3437943) — a triple agonist research peptide acting on the GLP-1, GIP and glucagon receptors.
6 min read →RetatrutideBackground on retatrutide in the academic literature — receptor pharmacology, study context and analytical handling.
8 min read →Product ComparisonsSide-by-side comparison of retatrutide and tirzepatide across receptor profile, research context and analytical considerations.
5 min read →Every batch of Tirzepatide ships with a third-party HPLC and mass-spec Certificate of Analysis. Browse the live COA library to verify your lot.
Long-term frozen storage (-20°C) is acceptable for lyophilised vials, but routine refrigerated storage at 2–8°C is sufficient for typical research timelines.
Read: Storage & Reconstitution →
